Innate Pharma SA
Change company Symbol lookup
Select an option...
IPHYF Innate Pharma SA
ROKU Roku Inc
HBAN Huntington Bancshares Inc
AICAF Air China Ltd
BTZ BlackRock Credit Allocation Income Trust
SLG SL Green Realty Corp
SKT Tanger Factory Outlet Centers Inc
SJR Shaw Communications Inc
SJM J M Smucker Co
SJI South Jersey Industries Inc
Go


Based in France
Company profile

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Closing Price
$4.72
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.72
Day's Low
4.72
Volume
(Heavy Day)
Volume:
200

10-day average volume:
200
200

Display:

Providers:

UpdateCancel
6 providers
January 05, 2021
Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

-- IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate's proprietary multispecific antibody format Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced that...(Globe Newswire)

January 04, 2021
Innate Pharma to Participate in Upcoming Investor Conferences

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences. (Globe Newswire)

December 11, 2020
Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca. Innate...(Globe Newswire)

December 03, 2020
Innate Pharma to Present Additional Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ESMO Immuno-Oncology Virtual Congress

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being...(Globe Newswire)

December 02, 2020
Innate Pharma 2021 Financial Calendar

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2021 financial calendar: All financial reports are released before market open CET. (Globe Newswire)

November 17, 2020
Innate Pharma Reports Third Quarter 2020 Financial Results and Business Update

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced its revenues and cash position for the first nine months of 2020. "In November, we were very pleased that our lead proprietary...(Globe Newswire)

November 13, 2020
Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in Sezary Syndrome

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the European Medicines Agency (EMA) has granted PRIME designation to lacutamab, the Company's proprietary first-in-class...(Globe Newswire)

November 12, 2020
Innate Pharma to Participate in upcoming investor conferences

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences. (Globe Newswire)

November 05, 2020
Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced the launch of HopeConnectLearn, a new online resource for the hairy cell leukemia community. HopeConnectLearn provides education...(Globe Newswire)

October 26, 2020
INNATE PHARMA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Innate Pharma S.A. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors that...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.